

Sarcoma Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



Sarcoma

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

First Line

Second Line

UCI 25-231

AIM vs No chemo + Sx

Coord: B. TBD

Accrual: 0/5

UCI 24-08

SPEDOX -6 (Protein encapsulated
doxorubicin)

Coord: E. Palmer-Torrison

Accrual: 5/50



Recurrent/Metastatic

UCI 24-175

Ziftomenib, Imatinib

Coord: B. Huynh

Accrual: 0/5

 Open to Accrual  Low Accruing  Pending Activation/Suspended

Supportive Care

UCI 24-05

Riluzole PO vs. Placebo PO
Perceived worsening of *cognitive function*

BREAST COHORT FULL

PI: Chan

CRC: Randy Kang

Accrual: 24/39

UCI 25-48

Riluzole PO vs. Placebo PO
Pts starting anthracycline/platinum agent

PI: Chan

CRC: Madeleine Phan

Accrual: 2/20

